These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 28270565

  • 1. Midostaurin, a Novel Protein Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia: Insights from Human Absorption, Metabolism, and Excretion Studies of a BDDCS II Drug.
    He H, Tran P, Gu H, Tedesco V, Zhang J, Lin W, Gatlik E, Klein K, Heimbach T.
    Drug Metab Dispos; 2017 May; 45(5):540-555. PubMed ID: 28270565
    [Abstract] [Full Text] [Related]

  • 2. Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers.
    Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y.
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1223-34. PubMed ID: 24085261
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report.
    Tollkuci E.
    J Oncol Pharm Pract; 2019 Jun; 25(4):987-989. PubMed ID: 29558838
    [Abstract] [Full Text] [Related]

  • 8. Dose- and time-dependent pharmacokinetics of midostaurin in patients with diabetes mellitus.
    Wang Y, Yin OQ, Graf P, Kisicki JC, Schran H.
    J Clin Pharmacol; 2008 Jun; 48(6):763-75. PubMed ID: 18508951
    [Abstract] [Full Text] [Related]

  • 9. Midostaurin for the treatment of acute myeloid leukemia.
    Patnaik MM.
    Future Oncol; 2017 Sep; 13(21):1853-1871. PubMed ID: 28610444
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML).
    Sechaud R, Sinclair K, Grosch K, Ouatas T, Pathak D.
    Cancer Chemother Pharmacol; 2022 Jul; 90(1):19-27. PubMed ID: 35751657
    [Abstract] [Full Text] [Related]

  • 11. Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin.
    Dutreix C, Lorenzo S, Wang Y.
    Eur J Clin Pharmacol; 2014 Aug; 70(8):915-20. PubMed ID: 24839948
    [Abstract] [Full Text] [Related]

  • 12. Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth.
    Peter B, Winter GE, Blatt K, Bennett KL, Stefanzl G, Rix U, Eisenwort G, Hadzijusufovic E, Gridling M, Dutreix C, Hoermann G, Schwaab J, Radia D, Roesel J, Manley PW, Reiter A, Superti-Furga G, Valent P.
    Leukemia; 2016 Feb; 30(2):464-72. PubMed ID: 26349526
    [Abstract] [Full Text] [Related]

  • 13. Absorption, metabolism, and excretion of [14C]ponatinib after a single oral dose in humans.
    Ye YE, Woodward CN, Narasimhan NI.
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):507-518. PubMed ID: 28184964
    [Abstract] [Full Text] [Related]

  • 14. Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells.
    Tvedt TH, Nepstad I, Bruserud Ø.
    Expert Opin Investig Drugs; 2017 Mar; 26(3):343-355. PubMed ID: 28001095
    [Abstract] [Full Text] [Related]

  • 15. Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.
    Takahashi RH, Choo EF, Ma S, Wong S, Halladay J, Deng Y, Rooney I, Gates M, Hop CE, Khojasteh SC, Dresser MJ, Musib L.
    Drug Metab Dispos; 2016 Jan; 44(1):28-39. PubMed ID: 26451002
    [Abstract] [Full Text] [Related]

  • 16. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
    Kayser S, Levis MJ, Schlenk RF.
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
    [Abstract] [Full Text] [Related]

  • 17. A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients.
    Cooper BW, Kindwall-Keller TL, Craig MD, Creger RJ, Hamadani M, Tse WW, Lazarus HM.
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):428-432.e2. PubMed ID: 25776192
    [Abstract] [Full Text] [Related]

  • 18. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
    Garcia JS, Percival ME.
    Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
    [Abstract] [Full Text] [Related]

  • 19. Management of Midostaurin-CYP3A4 Drug-Drug Interactions in Patients With Acute Myeloid Leukemia.
    Schlafer D.
    Oncology (Williston Park); 2019 Jul 16; 33(7):. PubMed ID: 31365750
    [No Abstract] [Full Text] [Related]

  • 20. Midostaurin: First Global Approval.
    Kim ES.
    Drugs; 2017 Jul 16; 77(11):1251-1259. PubMed ID: 28612232
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.